Physician profile
Alberto Lopez
NPI 1861430720
$969.00
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $469 · 2020: $197 · 2021: $193 · 2023: $91.91 · 2024: $18.12.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $110.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $164.30 | 2019-2020 | |
| Novo Nordisk INC | $125.59 | 2019-2021 | |
| Organogenesis INC. | $121.05 | 2021-2024 | Puraply |
| Merck Sharp & Dohme LLC | $77.64 | 2019-2021 | |
| Amgen INC. | $74.46 | 2019-2021 | |
| Amarin Pharma, INC. | $56.53 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $52.24 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $44.71 | 2019 | |
| Genentech USA, INC. | $37.05 | 2019 | |
| Lilly USA, LLC | $36.33 | 2019-2021 | |
| Pfizer INC. | $33.32 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.74 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $17.37 | 2019 | |
| Dexcom, INC. | $15.43 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $14.54 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adlon Therapeutics L.P. | $14.39 | 2020 | |
| Abbvie INC. | $13.79 | 2021 | |
| Shire North American Group INC | $13.35 | 2019 | |
| Daiichi Sankyo INC. | $12.32 | 2019 | |
| Sanofi Pasteur INC. | $11.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alberto Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.